SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 31, 2003
Progenics Pharmaceuticals, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-23143 13-3379479
--------------------------- ------------ -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
777 Old Saw Mill River Road, Tarrytown, New York 10591
------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (914) 789-2800
---------------
(Former name or former address, if changed since last report.)
Item 7. Financial Statements and Exhibits
(c) Exhibits
EXHIBIT NUMBER DESCRIPTION
Exhibit 99.1 Press Release dated March 31, 2003 of Progenics
Pharmaceuticals, Inc. (the "Company"), announcing its
results of operations for the fourth quarter and for
the year ended December 31, 2002 (filed herewith).
Exhibit 99.2 Press Release dated May 15, 2003 of the Company
announcing its results of operations for the first
quarter ended March 31, 2003 (filed herewith).
Item 9. Regulation FD Disclosure.
The information contained in this section is intended to be included under
"Item 12. Results of Operations and Financial Condition" and is included under
Item 9 in accordance with SEC Release No. 33-8216.
On March 31, 2003, the Company issued a press release announcing its
results of operations for the fourth quarter and for the year ended December 31,
2002. A copy of the press release is attached as Exhibit 99.1 to this report.
On May 15, 2003, the Company issued a press release announcing its results
of operations for the quarter ended March 31, 2003. A copy of the press release
is attached as Exhibit 99.2 to this report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PROGENICS PHARMACEUTICALS, INC.
By: /s/ PHILIP K. YACHMETZ
--------------------------------
Philip K. Yachmetz
Vice President, General Counsel and Secretary
Date: May 15, 2003